Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Keros Therapeutics (KROS) over the last 5 years, with Dec 2024 value amounting to $5.7 million.

  • Keros Therapeutics' Gains from Investment Securities was N/A to $5.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $22.5 million, marking a year-over-year change of. This contributed to the annual value of $5.7 million for FY2024, which is 328.77% up from last year.
  • According to the latest figures from FY2024, Keros Therapeutics' Gains from Investment Securities is $5.7 million, which was up 328.77% from $1.3 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Gains from Investment Securities ranged from a high of $15.4 million in FY2022 and a low of -$46,000 during FY2021.
  • Moreover, its 3-year median value for Gains from Investment Securities was $5.7 million (2024), whereas its average is $7.5 million.
  • As far as peak fluctuations go, Keros Therapeutics' Gains from Investment Securities soared by 33,628.26% in 2022, and later slumped by 91.32% in 2023.
  • Over the past 4 years, Keros Therapeutics' Gains from Investment Securities (Yearly) stood at -$46,000 in 2021, then surged by 33,628.26% to $15.4 million in 2022, then slumped by 91.32% to $1.3 million in 2023, then skyrocketed by 328.77% to $5.7 million in 2024.